thalidomide has been researched along with Liver Dysfunction in 10 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study was designed to investigate the preventive effect of thalidomide on acute pancreatitis-associated liver injury in the rat and analyze its relationship with oxidative stress." | 7.81 | Protective Effect of Thalidomide on Liver Injury in Rats with Acute Pancreatitis via Inhibition of Oxidative Stress. ( Fan, LJ; Li, HY; Liu, J; Lv, P; Meng, QS, 2015) |
| "This study was designed to investigate the preventive effect of thalidomide on acute pancreatitis-associated liver injury in the rat and analyze its relationship with oxidative stress." | 3.81 | Protective Effect of Thalidomide on Liver Injury in Rats with Acute Pancreatitis via Inhibition of Oxidative Stress. ( Fan, LJ; Li, HY; Liu, J; Lv, P; Meng, QS, 2015) |
| "Pomalidomide is an immunomodulatory drug and the dosage of 4 mg per day taken orally on days 1-21 of repeated 28-day cycles has been approved in the European Union and United States to treat patients with relapsed/refractory multiple myeloma." | 2.90 | An Open-Label, Phase 1 Study to Assess the Effects of Hepatic Impairment on Pomalidomide Pharmacokinetics. ( Gomez, D; Li, Y; Liu, L; Palmisano, M; Reyes, J; Wang, X; Zhang, C; Zhou, S, 2019) |
| "Thalidomide was originally developed as a sedative." | 2.49 | Clinical evidence of pharmacokinetic changes in thalidomide therapy. ( Ando, Y; Matsunaga, T; Matsuzawa, N; Nakamura, K; Ohmori, S; Yamazaki, H, 2013) |
| "Liver diseases are a major problem of worldwide proportions." | 2.44 | Beneficial drugs for liver diseases. ( Muriel, P; Rivera-Espinoza, Y, 2008) |
| "Thalidomide is a racemic glutamic acid derivative approved in the US for erythema nodosum leprosum, a complication of leprosy." | 2.42 | Clinical pharmacokinetics of thalidomide. ( Colburn, WA; Jaworsky, MS; Kook, KA; Laskin, OL; Scheffler, MA; Stirling, DI; Teo, SK; Thomas, SD; Tracewell, WG, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (20.00) | 18.7374 |
| 1990's | 1 (10.00) | 18.2507 |
| 2000's | 3 (30.00) | 29.6817 |
| 2010's | 4 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, Y | 1 |
| Wang, X | 1 |
| Liu, L | 1 |
| Zhang, C | 1 |
| Gomez, D | 1 |
| Reyes, J | 1 |
| Palmisano, M | 1 |
| Zhou, S | 1 |
| Lv, P | 1 |
| Fan, LJ | 1 |
| Li, HY | 1 |
| Meng, QS | 1 |
| Liu, J | 1 |
| Levesque, E | 1 |
| Bradette, M | 1 |
| Munoz, J | 1 |
| Janakiraman, N | 1 |
| Nakamura, K | 1 |
| Matsuzawa, N | 1 |
| Ohmori, S | 1 |
| Ando, Y | 1 |
| Yamazaki, H | 1 |
| Matsunaga, T | 1 |
| Friedman, L | 1 |
| Shue, GM | 1 |
| Hove, EL | 1 |
| Teo, SK | 1 |
| Colburn, WA | 1 |
| Tracewell, WG | 1 |
| Kook, KA | 1 |
| Stirling, DI | 1 |
| Jaworsky, MS | 1 |
| Scheffler, MA | 1 |
| Thomas, SD | 1 |
| Laskin, OL | 1 |
| Muriel, P | 1 |
| Rivera-Espinoza, Y | 1 |
| Aarestrup, FM | 1 |
| Gonçalves-da-Costa, SC | 1 |
| Sarno, EN | 1 |
| Madhavan, TV | 1 |
| Schaffner, F | 1 |
| Popper, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Observational Cohort Study Evaluating the Use and Efficacy of Pomalidomide in Patients With Multiple Myeloma in Routine Clinical Practice[NCT02902900] | 2,504 participants (Actual) | Observational | 2015-04-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for thalidomide and Liver Dysfunction
| Article | Year |
|---|---|
Clinical evidence of pharmacokinetic changes in thalidomide therapy.
Topics: Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Female; Food-Drug Interactions; Humans; Kid | 2013 |
Clinical pharmacokinetics of thalidomide.
Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Area Under Curve; Half-Life; Humans; Kidne | 2004 |
Beneficial drugs for liver diseases.
Topics: Adrenal Cortex Hormones; Animals; Colchicine; Curcumin; Disease Models, Animal; Drug Combinations; G | 2008 |
1 trial available for thalidomide and Liver Dysfunction
| Article | Year |
|---|---|
An Open-Label, Phase 1 Study to Assess the Effects of Hepatic Impairment on Pomalidomide Pharmacokinetics.
Topics: Aged; Area Under Curve; Healthy Volunteers; Humans; Immunologic Factors; Liver; Liver Diseases; Male | 2019 |
6 other studies available for thalidomide and Liver Dysfunction
| Article | Year |
|---|---|
Protective Effect of Thalidomide on Liver Injury in Rats with Acute Pancreatitis via Inhibition of Oxidative Stress.
Topics: Animals; Biomarkers; Glutathione Peroxidase; Intercellular Adhesion Molecule-1; Liver Diseases; Male | 2015 |
Hepatotoxicity as a rare but serious side effect of thalidomide.
Topics: Adult; Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Female; Humans; Liver Diseases | 2009 |
Relapse of liver amyloidosis 6 years after autologous stem cell transplantation.
Topics: Adult; Amyloidosis; Female; Humans; Lenalidomide; Liver Diseases; Magnetic Resonance Imaging; Periph | 2012 |
RESPONSE OF RATS TO THALIDOMIDE AS AFFECTED BY RIBOFLAVIN OR FOLIC ACID DEFICIENCY.
Topics: Amino Acid Oxidoreductases; Avitaminosis; D-Amino-Acid Oxidase; Electron Transport Complex II; Flavi | 1965 |
The effect of thalidomide on BCG-induced granulomas in mice.
Topics: Animals; Female; Granuloma; Liver Diseases; Mice; Mycobacterium Infections; Thalidomide; Tumor Necro | 1995 |
Catabolic and anabolic hepatotoxicity and nutrition.
Topics: Aflatoxins; Benzopyrenes; Carbon Tetrachloride Poisoning; DDT; Dieldrin; Ethionine; Foodborne Diseas | 1970 |